Abdelsalam Elshenawy R,Umaru N,Aslanpour Z N .2023 .WHO AWaRe classification for antibiotic stewardship: Tackling antimicrobial resistance - a descriptive study from an English NHS Foundation Trust prior to and during the COVID-19 pandemic. , 14 : 1298858.
Abdelwahab MT,Wasserman S,Brust JCM,Dheda K,Wiesner L,Gandhi NR,Warren RM,Sirgel FA,Meintjes G,Maartens G,Denti P .2021 .Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis. Antimicrob, 65(12) : e0138121.
Abe S,Chiba K,Cirincione B,Grasela TH,Ito K,Suwa T .2009 .Population pharmacokinetic analysis of 296 linezolid in patients with infectious disease: Application to lower body weight and elderly patients. J. Clin. Pharmacol, 49(9) : 1071-1078.
Alghamdi WA,Al-Shaer MH,An G,Alsultan A,Kipiani M,Barbakadze K,Mikiashvili L,Ashkin D,Griffith DE,Cegielski JP,Kempker RR,Peloquin CA .2020 .Population pharmacokinetics of linezolid in tuberculosis patients: Dosing regimen simulation and target attainment analysis. Antimicrob. Agents Chemother, 64(10) : e01174-01120.
Bai AD,McKenna S,Wise H,Loeb M,Gill SS M .2022 .Safety profile of linezolid in older adults with renal impairment: A population-based retrospective cohort study. Open Forum Infect. Dis., 9(12) : ofac669.
Boak LM,Rayner CR,Grayson ML,Paterson DL,Spelman D,Khumra S,Capitano B,Forrest A,Li J,Nation RL .2014 .Clinical population pharmacokinetics and toxicodynamics of linezolid. , 58(4) : 2334-2343.
Brier ME,Stalker DJ,Aronoff GR,Batts DH,Ryan KK,O'Grady M,Hopkins NK,Jungbluth GL .2003 .Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob, 47(9) : 2775-2780.
Caroline P and Linezolid J .2001 .A review of its use in the management of serious gram-positive infections. , 63(19) : 2126-2126.
Cattaneo D,Orlando G,Cozzi V,Cordier L,Baldelli S,Merli S,Fucile S,Gulisano C,Rizzardini G,Clementi EJIjoaa G .2013 .Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int. J. Antimicrob. Agents, 41(6) : 586-589.
Clemett D and Markham A .2000 .. Linezolid. Drugs, 59(4) : 815-827.
Cockcroft DW,Gault MH .1976 .Prediction of creatinine clearance from serum creatinine. Nephron, 16(1) : 31-41.
Dong H-Y J,Chen L-H,Wang T-T,Zhao Y-R,Dong Y-L .2014 .Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur. J. Clin. Microbiol, 33(6) : 1029-1035.
Dosne AG,Bergstrand M,Karlsson MO M .2016 .A strategy for residual error modeling incorporating scedasticity of variance and distribution shape. J. Pharmacokinet. Pharmacodyn., 43(2) : 137-151.
Dryden MS .2011 .Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J. Antimicrob. Chemother., 66(suppl) : 7-15.
Eekhout I,Heymans MW .2017 .Methods for significance testing of categorical covariates in logistic regression models after multiple imputation: Power and applicability analysis. BMC Med, 17(1) : 129.
Goodyear MD,Krleza-Jeric K,Lemmens T .2007 .. The declaration of Helsinki. BMJ, 335(7621) : 624-625.
Ippolito JA,Kanyo ZF,Wang D,Franceschi FJ,Moore PB,Steitz TA,Duffy EM .2008 .Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med, 51(12) : 3353-3356.
Keizer RJ,Van Benten M,Beijnen JH,Schellens JH,Huitema AD .2011 .Pirana and PCluster: A modeling environment and cluster infrastructure for NONMEM. Comput. Methods Programs Biomed. , 101(1) : 72-79.
Keutzer L,Mockeliunas L,Sturkenboom MGG,Bolhuis MS,Akkerman OW,Simonsson USH .2023 .Derivation and clinical utility of safety targets for linezolid-related adverse events in drug-resistant tuberculosis treatment. Pharmaceuticals (Basel), 16(11) : 1-18.
Leon Shargel ABY .2015 .Applied biopharmaceutics and Pharmacokinetics (7th ed. McGraw Hill Education., : .
Li SC,Ye Q,Xu H,Zhang L,Wang Y .2019 .Population pharmacokinetics and dosing optimization of linezolid in pediatric patients. Antimicrob, 63(4) : e02387-02318.
Lindbom L,Ribbing J,Jonsson EN .2004 .Perlspeaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput. Methods Programs, 75(2) : 85-94.
Minotti C,Bonadies L,Liberati C,De Pieri M,Giaquinto C,Baraldi E,Donà D .2022 .Enteral linezolid as an effective option to treat an extremely preterm infant with bacillus cereus sepsis. Children (Basel), 9(3) : 415.
Mockeliunas L,Keutzer L,Sturkenboom MGG,Bolhuis MS,Hulskotte LMG,Akkerman OW,Simonsson USH .2022 .Model-informed precision dosing of linezolid in patients with drug-resistant tuberculosis. Pharmaceutics, 14(4) : 753.
Paal M,Zoller M,Schuster C,Vogeser M,Schütze G. .2018 .Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC-MS/MS method. J. Pharm. Biomed. Anal., 152 : 102-110.
Qin Y,Zhang LL,Ye YR,Chen YT,Jiao Z. .2022 .Parametric population pharmacokinetics of linezolid: A systematic review. Br. J. Clin. Pharmacol, 88(9) : 4043-4066.
Rabon AD,Fisher JP,MacVane SHJAoP JP .2018 .Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater. , 52(11) : 1162-1164.
Rao GG,Konicki R,Cattaneo D,Alffenaar J-W,Marriott DJ,Neely M .2020 .Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: A review of linezolid pharmacokinetics and pharmacodynamics. , 42(1) : 83-92.
Reddy KK,Rao SM,Reddy GO,Suresh T,Babu JM,Dubey P,Vyas K P .2002 .Isolation and characterization of process-related impurities in linezolid. J. Pharm. Biomed. Anal., 30(3) : 635-642.
Roger C,Muller L,Wallis S,Louart B,Saissi G,Lipman J,Lefrant J,Roberts JA .2016 .Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: Comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J. Antimicrob. Chemother., 71(2) : 464-470.
Sasaki T,Takane H,Ogawa K,Isagawa S,Hirota T,Higuchi S,Horii T,Otsubo K,Ieiri I .2011 .Population Pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia in Japanese patients. , 55(5) : 1867-1873.
Sazdanovic P,Jankovic SM,Kostic M,Dimitrijevic A,Stefanovic S A .2016 .Pharmacokinetics of linezolid in critically ill patients. Expert Opin. Drug Metab. Toxicol., 12(6) : 595-600.
Soraluce A,Barrasa H,Asín-Prieto E,Sánchez-Izquierdo JÁ,Maynar J,Isla A,Rodríguez-Gascón A .2020 .Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation. Pharmaceutics, 12(1) : 54.
Swoboda S,Ober MC,Lichtenstern C,Saleh S,Schwenger V,Sonntag H-G,Haefeli WE,Hempel G,Hoppe-Tichy T,Weigand MA .2010 .Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Clinical Trial, 66(3) : 291-298.
Tsuji Y,Mizoguchi A,Sadoh S,Hiraki Y,Matsumoto K,Morita K,Kobayashi T,Kamimura H,Karube Y .2011 .Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J. Infect. Chemother., 17(1) : 70-75.
Tsuji Y,Yukawa E,Hiraki Y,Matsumoto K,Mizoguchi A,Morita K,Kamimura H,Karube Y,To H Y .2013 .Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J. Clin. Pharmacol, 53(9) : 967-973.
Vinh DC,Rubinstein E .2009 .Linezolid: A review of safety and tolerability. J. Infect. Chemother., 59 : S59-S74.
Wu F,Zhang XS,Dai Y,Zhou ZY,Zhang CH,Han L,Xu FM,Wang YX,Shi DW,Lin GY,Yu XB,Chen F XB .2022 .Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically ill patients. Front, 13 : 844567.
Xie F,Mantzarlis K,Malliotakis P,Koulouras V,Degroote S,Koulenti D,Blot S,Boussery K,Van Bocxlaer K,Colin P .2018 .Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia. J. Antimicrob. Chemother., 74(3) : 667-674.
Xu Y,Yang X,Liang P,Qu C .2023 .Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more. BMC Infect. Dis., 23(1) : 840.
Zhang H,He Y,Davies Forsman L,Paues J,Werngren J,Niward K,Schön T,Bruchfeld J,Alffenaar JW,Hu Y .2023 .Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrugresistant tuberculosis. Front, 13 : 1032674.
Zhang S-h,Li Z,Zou Y,Yan Y,Xu M,Wang Y,Liu F,Zhang B-K M-z .2020 .Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction. Antimicrob, 64(6) : e00133-00120.